For the depressed, dating can often be a challenge. Even smiling can be too much of an effort. It's called wearing “The mask of depression”. Here are some tips that can help interfacing with a potential emotional prospect a little easier. Medication. If you are depressed and on medication, take it religiously. Consistency is king. It will support you in dealing with friends and family, helping you to be a more upbeat, positive people. If you have a love prospect in hand, don’t tell him or her on the first date. Save that for when things are becoming more serious. Don’t feel compelled to do so before the time is right. When that happens you should begin by telling him or her that you have something about yourself that you need to talk about. Don't just blurt out "I suffer from depression!" Preface it by saying something something like you struggle with with a fairly common issue but that you are taking care of yourself by seeking treatment.

Demi Moore, despondent about the path of her acting career, is taking several prescription medications to deal with her anxiety and depression. She has a long history of anorexia and has also been reported to be taking a prescription of the ADD, focus, medication Adderall with her energy drinks. The combination is believed to be the reason for her collapse on a couple of months ago. ON January 23 Demi experienced a seizure. Her very public separation to Ashton combined with dissatisfaction over her stalled career has been rough on her. And, of course there were the allegations that Mr. Kutcher cheated on her.

Researchers say they have developed a blood test that may reliably detect depression. Experts say it could become one of the first objective ways to assess depression via hormones, growth factors and proteins. “Psychiatry is a field that is begging for tests because all of our diagnoses, for the most part, are based on clinical assessments, and clinical assessments are very subjective and can be biased,” says Jennifer L. Payne, MD, a psychiatrist and co-director of the Mood Disorders Center at Johns Hopkins Hospital in Baltimore. The study was published in the journal Molecular Psychiatry.  Another study, involving 70 people with depression (and 43 people who were not) correctly identified depression about 91% of the time, ruling it out 81% of the time. “Chronic inflammation is a big risk factor or part of the process of depression itself,” says an associate professor of psychiatry at Harvard Medical School. Additional indicators include hormones, growth factors, enzymes, and other proteins that act as chemical messengers.

Valentine’s Day next week means literally millions across the country will flock to candy stores, flower shops and favorite restaurants to let that special someone know how much they care. Excellent ideas all. Oxytocin Accelerator approaches Valentine's Day from a more logical stance, the logic being that love is always with us; in our genes, our chemistry, our evolutionary past, our whole nature and there is no faster way to release it.
Click here to read more.

Abstract
St. John's Wort (SJW) has been used medicinally for over 5,000 years. Relatively recently, one of its phloroglucinol derivatives, hyperforin, has emerged as a compound of interest. Hyperforin first gained attention as the constituent of SJW responsible for its antidepressant effects. Since then, several of its neurobiological effects have been described, including neurotransmitter re-uptake inhibition, the ability to increase intracellular sodium and calcium levels, canonical transient receptor potential 6 (TRPC6) activation, N-methyl-D-aspartic acid (NMDA) receptor antagonism as well as antioxidant and anti-inflammatory properties. Until recently, its pharmacological actions outside of depression had not been investigated. However, hyperforin has been shown to have cognitive enhancing and memory facilitating properties. Importantly, it has been shown to have neuroprotective effects against Alzheimer's disease (AD) neuropathology, including the ability to disassemble amyloid-beta (Abeta) aggregates in vitro, decrease astrogliosis and microglia activation, as well as improve spatial memory in vivo. This review will examine some of the early studies involving hyperforin and its effects in the central nervous system (CNS), with an emphasis on its potential use in AD therapy. With further investigation, hyperforin could emerge to be a likely therapeutical candidate in the treatment of this disease.